{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T16:14:39Z","timestamp":1781712879859,"version":"3.54.5"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":29,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100006344","name":"Fondazione Sandro Pitigliani","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006344","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020581","name":"Fondazione AIRC per la ricerca sul cancro ETS","doi-asserted-by":"publisher","award":["29370"],"award-info":[{"award-number":["29370"]}],"id":[{"id":"10.13039\/100020581","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020581","name":"Fondazione AIRC per la ricerca sul cancro ETS","doi-asserted-by":"publisher","award":["27036"],"award-info":[{"award-number":["27036"]}],"id":[{"id":"10.13039\/100020581","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["GR-2018-12365195"],"award-info":[{"award-number":["GR-2018-12365195"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Genome Med"],"DOI":"10.1186\/s13073-026-01603-3","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T07:05:48Z","timestamp":1770102348000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A computational framework for sensitive tumor detection and accurate subtyping using shallow cell-free DNA methylome sequencing"],"prefix":"10.1186","volume":"18","author":[{"given":"Marta","family":"Paoli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Galardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agostina","family":"Nardone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Biagioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Romagnoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Di Donato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gian Marco","family":"Franceschini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Livraghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Pestrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina","family":"Sanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Risi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilenia","family":"Migliaccio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Moretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Malorni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Biganzoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Demichelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Benelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"key":"1603_CR1","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/s43018-020-0043-5","volume":"1","author":"DW Cescon","year":"2020","unstructured":"Cescon DW, Bratman SV, Chan SM, Siu LL. Circulating tumor DNA and liquid biopsy in oncology. Nat Cancer. 2020;1:276\u201390. https:\/\/doi.org\/10.1038\/s43018-020-0043-5.","journal-title":"Nat Cancer"},{"key":"1603_CR2","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/nrclinonc.2017.14","volume":"14","author":"G Siravegna","year":"2017","unstructured":"Siravegna G, Marsoni S, Siena S, Bardelli A. Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol. 2017;14:531\u201348. https:\/\/doi.org\/10.1038\/nrclinonc.2017.14.","journal-title":"Nat Rev Clin Oncol"},{"key":"1603_CR3","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.annonc.2023.12.007","volume":"35","author":"MA Gouda","year":"2024","unstructured":"Gouda MA, Janku F, Wahida A, Buschhorn L, Schneeweiss A, Abdel Karim N, et al. Liquid biopsy response evaluation criteria in solid tumors (LB-RECIST). Ann Oncol. 2024;35:267\u201375. https:\/\/doi.org\/10.1016\/j.annonc.2023.12.007.","journal-title":"Ann Oncol"},{"key":"1603_CR4","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/s41571-020-00457-x","volume":"18","author":"M Ignatiadis","year":"2021","unstructured":"Ignatiadis M, Sledge GW, Jeffrey SS. Liquid biopsy enters the clinic - implementation issues and future challenges. Nat Rev Clin Oncol. 2021;18:297\u2013312. https:\/\/doi.org\/10.1038\/s41571-020-00457-x.","journal-title":"Nat Rev Clin Oncol"},{"key":"1603_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.09.163","author":"ZR Reichert","year":"2022","unstructured":"Reichert ZR, Morgan TM, Li G, Castellanos E, Snow T, Dall\u2019Olio FG, et al. Prognostic value of plasma Circulating tumor DNA fraction across four common cancer types: a real-world outcomes study. Ann Oncol [Internet]. 2022. https:\/\/doi.org\/10.1016\/j.annonc.2022.09.163.","journal-title":"Ann Oncol [Internet]"},{"key":"1603_CR6","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1200\/JCO.2017.76.0033","volume":"36","author":"DG Stover","year":"2018","unstructured":"Stover DG, Parsons HA, Ha G, Freeman SS, Barry WT, Guo H, et al. Association of cell-free DNA tumor fraction and somatic copy number alterations with survival in metastatic triple-negative breast cancer. J Clin Oncol. 2018;36:543\u201353. https:\/\/doi.org\/10.1200\/JCO.2017.76.0033.","journal-title":"J Clin Oncol"},{"key":"1603_CR7","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1056\/NEJMoa1213261","volume":"368","author":"S-J Dawson","year":"2013","unstructured":"Dawson S-J, Tsui DWY, Murtaza M, Biggs H, Rueda OM, Chin S-F, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med. 2013;368:1199\u2013209. https:\/\/doi.org\/10.1056\/NEJMoa1213261.","journal-title":"N Engl J Med"},{"key":"1603_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-021-00898-8","volume":"13","author":"DWY Tsui","year":"2021","unstructured":"Tsui DWY, Cheng ML, Shady M, Yang JL, Stephens D, Won H, et al. Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients. Genome Med. 2021;13:96. https:\/\/doi.org\/10.1186\/s13073-021-00898-8.","journal-title":"Genome Med"},{"key":"1603_CR9","doi-asserted-by":"publisher","first-page":"e2200261","DOI":"10.1200\/PO.22.00261","volume":"6","author":"H Husain","year":"2022","unstructured":"Husain H, Pavlick DC, Fendler BJ, Madison RW, Decker B, Gjoerup O, et al. Tumor fraction correlates with detection of actionable variants across >\u200923,000 Circulating tumor DNA samples. JCO Precis Oncol. 2022;6:e2200261. https:\/\/doi.org\/10.1200\/PO.22.00261.","journal-title":"JCO Precis Oncol"},{"key":"1603_CR10","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1172\/JCI131041","volume":"130","author":"H Beltran","year":"2020","unstructured":"Beltran H, Romanel A, Conteduca V, Casiraghi N, Sigouros M, Franceschini GM, et al. Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer. J Clin Invest. 2020;130:1653\u201368. https:\/\/doi.org\/10.1172\/JCI131041.","journal-title":"J Clin Invest"},{"key":"1603_CR11","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1158\/2159-8290.CD-23-0754","volume":"14","author":"GM Franceschini","year":"2024","unstructured":"Franceschini GM, Quaini O, Mizuno K, Orlando F, Ciani Y, Ku S-Y, et al. Noninvasive detection of neuroendocrine prostate cancer through targeted Cell-free DNA methylation. Cancer Discov. 2024;14:424\u201345. https:\/\/doi.org\/10.1158\/2159-8290.CD-23-0754.","journal-title":"Cancer Discov"},{"key":"1603_CR12","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aac9511","volume":"7","author":"A Romanel","year":"2015","unstructured":"Romanel A, Gasi Tandefelt D, Conteduca V, Jayaram A, Casiraghi N, Wetterskog D, et al. Plasma AR and abiraterone-resistant prostate cancer. Sci Transl Med. 2015;7:312re10-312re10. https:\/\/doi.org\/10.1126\/scitranslmed.aac9511.","journal-title":"Sci Transl Med"},{"key":"1603_CR13","doi-asserted-by":"publisher","DOI":"10.1093\/narcan\/zcac016","volume":"4","author":"F Orlando","year":"2022","unstructured":"Orlando F, Romanel A, Trujillo B, Sigouros M, Wetterskog D, Quaini O, et al. Allele-informed copy number evaluation of plasma DNA samples from metastatic prostate cancer patients: the PCF_SELECT consortium assay. NAR Cancer. 2022;4:zcac016. https:\/\/doi.org\/10.1093\/narcan\/zcac016.","journal-title":"NAR Cancer"},{"key":"1603_CR14","doi-asserted-by":"publisher","first-page":"2452","DOI":"10.1158\/1078-0432.CCR-23-3321","volume":"30","author":"CD Rolfo","year":"2024","unstructured":"Rolfo CD, Madison RW, Pasquina LW, Brown DW, Huang Y, Hughes JD, et al. Measurement of ctDNA tumor fraction identifies informative negative liquid biopsy results and informs value of tissue confirmation. Clin Cancer Res. 2024;30:2452\u201360. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-3321.","journal-title":"Clin Cancer Res"},{"key":"1603_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24109-5","volume":"12","author":"A Rose Brannon","year":"2021","unstructured":"Rose Brannon A, Jayakumaran G, Diosdado M, Patel J, Razumova A, Hu Y, et al. Enhanced specificity of clinical high-sensitivity tumor mutation profiling in cell-free DNA via paired normal sequencing using MSK-ACCESS. Nat Commun. 2021;12:3770. https:\/\/doi.org\/10.1038\/s41467-021-24109-5.","journal-title":"Nat Commun"},{"key":"1603_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00965-y","volume":"8","author":"VA Adalsteinsson","year":"2017","unstructured":"Adalsteinsson VA, Ha G, Freeman SS, Choudhury AD, Stover DG, Parsons HA, et al. Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. Nat Commun. 2017;8:1324. https:\/\/doi.org\/10.1038\/s41467-017-00965-y.","journal-title":"Nat Commun"},{"key":"1603_CR17","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/s41586-019-1272-6","volume":"570","author":"S Cristiano","year":"2019","unstructured":"Cristiano S, Leal A, Phallen J, Fiksel J, Adleff V, Bruhm DC, et al. Genome-wide cell-free DNA fragmentation in patients with cancer. Nature. 2019;570:385\u20139. https:\/\/doi.org\/10.1038\/s41586-019-1272-6.","journal-title":"Nature"},{"key":"1603_CR18","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/s41586-018-0703-0","volume":"563","author":"SY Shen","year":"2018","unstructured":"Shen SY, Singhania R, Fehringer G, Chakravarthy A, Roehrl MHA, Chadwick D, et al. Sensitive tumour detection and classification using plasma cell-free DNA methylomes. Nature. 2018;563:579\u201383. https:\/\/doi.org\/10.1038\/s41586-018-0703-0.","journal-title":"Nature"},{"key":"1603_CR19","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.SABCS21-GS3-07","volume":"82","author":"G Bianchini","year":"2022","unstructured":"Bianchini G, Malorni L, Arpino G, Zambelli A, Puglisi F, Mastro LD, et al. Abstract GS3-07: Circulating tumor DNA (ctDNA) dynamics in patients with hormone receptor positive (HR+)\/HER2 negative (HER2-) advanced breast cancer (aBC) treated in first line with ribociclib (R) and letrozole (L) in the BioItaLEE trial. Cancer Res. 2022;82:GS3-07-GS3-07. https:\/\/doi.org\/10.1158\/1538-7445.SABCS21-GS3-07.","journal-title":"Cancer Res"},{"key":"1603_CR20","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1172\/JCI130887","volume":"130","author":"A Wu","year":"2020","unstructured":"Wu A, Cremaschi P, Wetterskog D, Conteduca V, Franceschini GM, Kleftogiannis D, et al. Genome-wide plasma DNA methylation features of metastatic prostate cancer. J Clin Invest. 2020;130:1991\u20132000. https:\/\/doi.org\/10.1172\/JCI130887.","journal-title":"J Clin Invest"},{"key":"1603_CR21","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1038\/s41591-023-02605-z","volume":"29","author":"SC Baca","year":"2023","unstructured":"Baca SC, Seo J-H, Davidsohn MP, Fortunato B, Semaan K, Sotudian S, et al. Liquid biopsy epigenomic profiling for cancer subtyping. Nat Med. 2023;29:2737\u201341. https:\/\/doi.org\/10.1038\/s41591-023-02605-z.","journal-title":"Nat Med"},{"key":"1603_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-41774-w","volume":"14","author":"F Bie","year":"2023","unstructured":"Bie F, Wang Z, Li Y, Guo W, Hong Y, Han T, et al. Multimodal analysis of cell-free DNA whole-methylome sequencing for cancer detection and localization. Nat Commun. 2023;14:6042. https:\/\/doi.org\/10.1038\/s41467-023-41774-w.","journal-title":"Nat Commun"},{"key":"1603_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-35076-w","volume":"13","author":"A-L Doebley","year":"2022","unstructured":"Doebley A-L, Ko M, Liao H, Cruikshank AE, Santos K, Kikawa C, et al. A framework for clinical cancer subtyping from nucleosome profiling of cell-free DNA. Nat Commun. 2022;13:7475. https:\/\/doi.org\/10.1038\/s41467-022-35076-w.","journal-title":"Nat Commun"},{"key":"1603_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46435-0","volume":"15","author":"KE Stanley","year":"2024","unstructured":"Stanley KE, Jatsenko T, Tuveri S, Sudhakaran D, Lannoo L, Van Calsteren K, et al. Cell type signatures in cell-free DNA fragmentation profiles reveal disease biology. Nat Commun. 2024;15:2220. https:\/\/doi.org\/10.1038\/s41467-024-46435-0.","journal-title":"Nat Commun"},{"key":"1603_CR25","doi-asserted-by":"publisher","first-page":"18761","DOI":"10.1073\/pnas.1313995110","volume":"110","author":"KCA Chan","year":"2013","unstructured":"Chan KCA, Jiang P, Chan CWM, Sun K, Wong J, Hui EP, et al. Noninvasive detection of cancer-associated genome-wide hypomethylation and copy number aberrations by plasma DNA bisulfite sequencing. Proc Natl Acad Sci U S A. 2013;110:18761\u20138. https:\/\/doi.org\/10.1073\/pnas.1313995110.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1603_CR26","doi-asserted-by":"publisher","first-page":"E5503","DOI":"10.1073\/pnas.1508736112","volume":"112","author":"K Sun","year":"2015","unstructured":"Sun K, Jiang P, Chan KCA, Wong J, Cheng YKY, Liang RHS, et al. Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessments. Proc Natl Acad Sci U S A. 2015;112:E5503-5512. https:\/\/doi.org\/10.1073\/pnas.1508736112.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1603_CR27","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbad015","author":"D Romagnoli","year":"2023","unstructured":"Romagnoli D, Nardone A, Galardi F, Paoli M, De Luca F, Biagioni C, et al. MIMESIS: minimal DNA-methylation signatures to quantify and classify tumor signals in tissue and cell-free DNA samples. Brief Bioinform. 2023. https:\/\/doi.org\/10.1093\/bib\/bbad015.","journal-title":"Brief Bioinform"},{"key":"1603_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-025-00739-6","volume":"11","author":"R Scandino","year":"2025","unstructured":"Scandino R, Nardone A, Casiraghi N, Galardi F, Genovese M, Romagnoli D, et al. Enabling sensitive and precise detection of ctDNA through somatic copy number aberrations in breast cancer. Npj Breast Cancer. 2025;11:25. https:\/\/doi.org\/10.1038\/s41523-025-00739-6.","journal-title":"Npj Breast Cancer"},{"key":"1603_CR29","doi-asserted-by":"publisher","first-page":"26107","DOI":"10.18632\/oncotarget.8431","volume":"7","author":"F De Luca","year":"2016","unstructured":"De Luca F, Rotunno G, Salvianti F, Galardi F, Pestrin M, Gabellini S, et al. Mutational analysis of single circulating tumor cells by next generation sequencing in metastatic breast cancer. Oncotarget. 2016;7:26107\u201319. https:\/\/doi.org\/10.18632\/oncotarget.8431.","journal-title":"Oncotarget"},{"key":"1603_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-021-01415-w","volume":"23","author":"F Galardi","year":"2021","unstructured":"Galardi F, De Luca F, Biagioni C, Migliaccio I, Curigliano G, Minisini AM, et al. Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TREnd trial. Breast Cancer Res. 2021;23:38. https:\/\/doi.org\/10.1186\/s13058-021-01415-w.","journal-title":"Breast Cancer Res"},{"key":"1603_CR31","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.molonc.2014.12.001","volume":"9","author":"M Pestrin","year":"2015","unstructured":"Pestrin M, Salvianti F, Galardi F, De Luca F, Turner N, Malorni L, et al. Heterogeneity of PIK3CA mutational status at the single cell level in circulating tumor cells from metastatic breast cancer patients. Mol Oncol. 2015;9:749\u201357. https:\/\/doi.org\/10.1016\/j.molonc.2014.12.001.","journal-title":"Mol Oncol"},{"key":"1603_CR32","doi-asserted-by":"publisher","first-page":"S500","DOI":"10.1016\/j.annonc.2025.08.1347","volume":"36","author":"S Di Donato","year":"2025","unstructured":"Di Donato S, Malinconi S, Galardi F, Cantafio S, Orioli T, Biagioni C, et al. 774p clinical and molecular profiling of high-risk localized colorectal cancer (CRC) in the LIBIMET trial. Ann Oncol. 2025;36:S500. https:\/\/doi.org\/10.1016\/j.annonc.2025.08.1347.","journal-title":"Ann Oncol"},{"key":"1603_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-14098-x","volume":"11","author":"J Achinger-Kawecka","year":"2020","unstructured":"Achinger-Kawecka J, Valdes-Mora F, Luu P-L, Giles KA, Caldon CE, Qu W, et al. Epigenetic reprogramming at estrogen-receptor binding sites alters 3D chromatin landscape in endocrine-resistant breast cancer. Nat Commun. 2020;11:320. https:\/\/doi.org\/10.1038\/s41467-019-14098-x.","journal-title":"Nat Commun"},{"key":"1603_CR34","doi-asserted-by":"publisher","DOI":"10.1093\/gigascience\/giab008","volume":"10","author":"P Danecek","year":"2021","unstructured":"Danecek P, Bonfield JK, Liddle J, Marshall J, Ohan V, Pollard MO, et al. Twelve years of SAMtools and BCFtools. Gigascience. 2021;10:giab008. https:\/\/doi.org\/10.1093\/gigascience\/giab008.","journal-title":"Gigascience"},{"key":"1603_CR35","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/s41587-020-0439-x","volume":"38","author":"PA Ewels","year":"2020","unstructured":"Ewels PA, Peltzer A, Fillinger S, Patel H, Alneberg J, Wilm A, et al. The nf-core framework for community-curated bioinformatics pipelines. Nat Biotechnol. 2020;38:276\u20138. https:\/\/doi.org\/10.1038\/s41587-020-0439-x.","journal-title":"Nat Biotechnol"},{"key":"1603_CR36","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1093\/bioinformatics\/btr167","volume":"27","author":"F Krueger","year":"2011","unstructured":"Krueger F, Andrews SR. Bismark: a flexible aligner and methylation caller for Bisulfite-Seq applications. Bioinformatics. 2011;27:1571\u20132. https:\/\/doi.org\/10.1093\/bioinformatics\/btr167.","journal-title":"Bioinformatics"},{"key":"1603_CR37","unstructured":"Krueger F. Trim Galore. https:\/\/www.bioinformatics.babraham.ac.uk\/projects\/trim_galore."},{"key":"1603_CR38","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-021-02761-3","volume":"4","author":"M Benelli","year":"2021","unstructured":"Benelli M, Franceschini GM, Magi A, Romagnoli D, Biagioni C, Migliaccio I, et al. Charting differentially methylated regions in cancer with Rocker-meth. Commun Biol. 2021;4:1249. https:\/\/doi.org\/10.1038\/s42003-021-02761-3.","journal-title":"Commun Biol"},{"key":"1603_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-09828-0","volume":"10","author":"AB Brinkman","year":"2019","unstructured":"Brinkman AB, Nik-Zainal S, Simmer F, Rodr\u00edguez-Gonz\u00e1lez FG, Smid M, Alexandrov LB, et al. Partially methylated domains are hypervariable in breast cancer and fuel widespread CpG island hypermethylation. Nat Commun. 2019;10:1749. https:\/\/doi.org\/10.1038\/s41467-019-09828-0.","journal-title":"Nat Commun"},{"key":"1603_CR40","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/s41586-022-05580-6","volume":"613","author":"N Loyfer","year":"2023","unstructured":"Loyfer N, Magenheim J, Peretz A, Cann G, Bredno J, Klochendler A, et al. A DNA methylation atlas of normal human cell types. Nature. 2023;613:355\u201364. https:\/\/doi.org\/10.1038\/s41586-022-05580-6.","journal-title":"Nature"},{"key":"1603_CR41","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1165\/rcmb.2019-0150TR","volume":"61","author":"BD Singer","year":"2019","unstructured":"Singer BD. A practical guide to the measurement and analysis of DNA methylation. Am J Respir Cell Mol Biol. 2019;61:417\u201328. https:\/\/doi.org\/10.1165\/rcmb.2019-0150TR.","journal-title":"Am J Respir Cell Mol Biol"},{"key":"1603_CR42","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gky423","volume":"46","author":"W Li","year":"2018","unstructured":"Li W, Li Q, Kang S, Same M, Zhou Y, Sun C, et al. CancerDetector: ultrasensitive and non-invasive cancer detection at the resolution of individual reads using cell-free DNA methylation sequencing data. Nucleic Acids Res. 2018;46:e89. https:\/\/doi.org\/10.1093\/nar\/gky423.","journal-title":"Nucleic Acids Res"},{"key":"1603_CR43","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s12859-017-1511-5","volume":"18","author":"AE Teschendorff","year":"2017","unstructured":"Teschendorff AE, Breeze CE, Zheng SC, Beck S. A comparison of reference-based algorithms for correcting cell-type heterogeneity in epigenome-wide association studies. BMC Bioinformatics. 2017;18:105. https:\/\/doi.org\/10.1186\/s12859-017-1511-5.","journal-title":"BMC Bioinformatics"},{"key":"1603_CR44","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1038\/s43018-022-00415-9","volume":"3","author":"F Chemi","year":"2022","unstructured":"Chemi F, Pearce SP, Clipson A, Hill SM, Conway A-M, Richardson SA, et al. cfDNA methylome profiling for detection and subtyping of small cell lung cancers. Nat Cancer. 2022;3:1260\u201370. https:\/\/doi.org\/10.1038\/s43018-022-00415-9.","journal-title":"Nat Cancer"},{"key":"1603_CR45","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbac200","volume":"23","author":"Q Wei","year":"2022","unstructured":"Wei Q, Jin C, Wang Y, Guo S, Guo X, Liu X, et al. A computational framework to unify orthogonal information in DNA methylation and copy number aberrations in cell-free DNA for early cancer detection. Brief Bioinform. 2022;23:bbac200. https:\/\/doi.org\/10.1093\/bib\/bbac200.","journal-title":"Brief Bioinform"},{"key":"1603_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-024-00706-7","volume":"10","author":"T Thomas-Bonafos","year":"2024","unstructured":"Thomas-Bonafos T, Pierga JY, Bidard F-C, Cabel L, Kiavue N. Circulating tumor cells in breast cancer: clinical validity and utility. NPJ Breast Cancer. 2024;10:103. https:\/\/doi.org\/10.1038\/s41523-024-00706-7.","journal-title":"NPJ Breast Cancer"},{"key":"1603_CR47","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1056\/NEJMoa040766","volume":"351","author":"M Cristofanilli","year":"2004","unstructured":"Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med. 2004;351:781\u201391. https:\/\/doi.org\/10.1056\/NEJMoa040766.","journal-title":"N Engl J Med"},{"key":"1603_CR48","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1200\/JCO.2011.37.2482","volume":"30","author":"LS Lindstr\u00f6m","year":"2012","unstructured":"Lindstr\u00f6m LS, Karlsson E, Wilking UM, Johansson U, Hartman J, Lidbrink EK, et al. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. J Clin Oncol. 2012;30:2601\u20138. https:\/\/doi.org\/10.1200\/JCO.2011.37.2482.","journal-title":"J Clin Oncol"},{"key":"1603_CR49","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-023-00550-1","volume":"9","author":"S Morganti","year":"2023","unstructured":"Morganti S, Parsons HA, Lin NU, Grinshpun A. Liquid biopsy for brain metastases and leptomeningeal disease in patients with breast cancer. NPJ Breast Cancer. 2023;9:43. https:\/\/doi.org\/10.1038\/s41523-023-00550-1.","journal-title":"NPJ Breast Cancer"},{"key":"1603_CR50","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/bty011","author":"M Benelli","year":"2018","unstructured":"Benelli M, Romagnoli D, Demichelis F. Tumor purity quantification by clonal DNA methylation signatures. Bioinformatics. 2018. https:\/\/doi.org\/10.1093\/bioinformatics\/bty011.","journal-title":"Bioinformatics"},{"key":"1603_CR51","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.cell.2018.03.022","volume":"173","author":"KA Hoadley","year":"2018","unstructured":"Hoadley KA, Yau C, Hinoue T, Wolf DM, Lazar AJ, Drill E, et al. Cell-of-origin patterns dominate the molecular classification of 10,000 tumors from 33 types of cancer. Cell. 2018;173:291-304.e6. https:\/\/doi.org\/10.1016\/j.cell.2018.03.022.","journal-title":"Cell"},{"key":"1603_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36801-9","volume":"14","author":"A Prat","year":"2023","unstructured":"Prat A, Bras\u00f3-Maristany F, Mart\u00ednez-S\u00e1ez O, Sanfeliu E, Xia Y, Bellet M, et al. Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancer. Nat Commun. 2023;14:1157. https:\/\/doi.org\/10.1038\/s41467-023-36801-9.","journal-title":"Nat Commun"},{"key":"1603_CR53","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1093\/jnci\/djx273","volume":"110","author":"WAME Schrijver","year":"2018","unstructured":"Schrijver WAME, Suijkerbuijk KPM, van Gils CH, van der Wall E, Moelans CB, van Diest PJ. Receptor conversion in distant breast cancer metastases: a systematic review and meta-analysis. J Natl Cancer Inst. 2018;110:568\u201380. https:\/\/doi.org\/10.1093\/jnci\/djx273.","journal-title":"J Natl Cancer Inst"},{"key":"1603_CR54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10549-021-06390-6","volume":"191","author":"S Shiino","year":"2022","unstructured":"Shiino S, Ball G, Syed BM, Kurozumi S, Green AR, Tsuda H, et al. Prognostic significance of receptor expression discordance between primary and recurrent breast cancers: a meta-analysis. Breast Cancer Res Treat. 2022;191:1\u201314. https:\/\/doi.org\/10.1007\/s10549-021-06390-6.","journal-title":"Breast Cancer Res Treat"},{"key":"1603_CR55","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1158\/2159-8290.CD-20-1647","volume":"11","author":"P Aftimos","year":"2021","unstructured":"Aftimos P, Oliveira M, Irrthum A, Fumagalli D, Sotiriou C, Gal-Yam EN, et al. Genomic and transcriptomic analyses of breast cancer primaries and matched metastases in AURORA, the Breast International Group (BIG) molecular screening initiative. Cancer Discov. 2021;11:2796\u2013811. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-1647.","journal-title":"Cancer Discov"},{"key":"1603_CR56","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1038\/s43018-022-00491-x","volume":"4","author":"S Garcia-Recio","year":"2023","unstructured":"Garcia-Recio S, Hinoue T, Wheeler GL, Kelly BJ, Garrido-Castro AC, Pascual T, et al. Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis. Nat Cancer. 2023;4:128\u201347. https:\/\/doi.org\/10.1038\/s43018-022-00491-x.","journal-title":"Nat Cancer"},{"key":"1603_CR57","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1158\/0008-5472.CAN-16-2717","volume":"77","author":"JM Cejalvo","year":"2017","unstructured":"Cejalvo JM, de Due\u00f1as EM, Galv\u00e1n P, Garc\u00eda-Recio S, Gasi\u00f3n OB, Par\u00e9 L, et al. Intrinsic subtypes and gene expression profiles in primary and metastatic breast cancer. Cancer Res. 2017;77:2213\u201321. https:\/\/doi.org\/10.1158\/0008-5472.CAN-16-2717.","journal-title":"Cancer Res"},{"key":"1603_CR58","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1093\/neuonc\/noaa013","volume":"22","author":"AFC Hulsbergen","year":"2020","unstructured":"Hulsbergen AFC, Claes A, Kavouridis VK, Ansaripour A, Nogarede C, Hughes ME, et al. Subtype switching in breast cancer brain metastases: a multicenter analysis. Neuro-Oncology. 2020;22:1173\u201381. https:\/\/doi.org\/10.1093\/neuonc\/noaa013.","journal-title":"Neuro-Oncology"},{"issue":"4","key":"1603_CR59","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/S1470-2045(14)70069-5","volume":"15","author":"F-C Bidard","year":"2014","unstructured":"Bidard F-C, Peeters DJ, Fehm T, Nol\u00e9 F, Gisbert-Criado R, Mavroudis D, et al. Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data. Lancet Oncol. 2014;15(4):406. https:\/\/doi.org\/10.1016\/S1470-2045(14)70069-5.","journal-title":"Lancet Oncol"},{"issue":"3","key":"1603_CR60","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s10147-017-1105-2","volume":"22","author":"L Cabel","year":"2017","unstructured":"Cabel L, Proudhon C, Gortais H, Loirat D, Coussy F, Pierga J-Y, et al. Circulating tumor cells: clinical validity and utility. Int J Clin Oncol. 2017;22(3):421. https:\/\/doi.org\/10.1007\/s10147-017-1105-2.","journal-title":"Int J Clin Oncol"},{"issue":"12","key":"1603_CR61","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1001\/jamaoncol.2018.2574","volume":"4","author":"J Sparano","year":"2018","unstructured":"Sparano J, O\u2019Neill A, Alpaugh K, Wolff AC, Northfelt DW, Dang CT, et al. Association of circulating tumor cells with late recurrence of estrogen receptor-positive breast cancer: a secondary analysis of a randomized clinical trial. JAMA Oncol. 2018;4:1700. https:\/\/doi.org\/10.1001\/jamaoncol.2018.2574.","journal-title":"JAMA Oncol"},{"issue":"9","key":"1603_CR62","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1001\/jamaoncol.2019.1467","volume":"5","author":"F Pietrantonio","year":"2019","unstructured":"Pietrantonio F, Morano F, Corallo S, Miceli R, Lonardi S, Raimondi A, et al. Maintenance therapy with panitumumab alone vs panitumumab plus fluorouracil-leucovorin in patients with RAS wild-type metastatic colorectal cancer: a phase 2 randomized clinical trial. JAMA Oncol. 2019;5:1268. https:\/\/doi.org\/10.1001\/jamaoncol.2019.1467.","journal-title":"JAMA Oncol"},{"key":"1603_CR63","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-25-2773","author":"P Manca","year":"2025","unstructured":"Manca P, Paoli M, Galardi F, Morano F, Di Donato S, Biganzoli L, et al. CtDNA detection with low-pass whole genome bisulfite sequencing in RAS wild-type metastatic colorectal cancer: an exploratory objective of the VALENTINO trial. Clin Cancer Res Off J Am Assoc Cancer Res. 2025. https:\/\/doi.org\/10.1158\/1078-0432.CCR-25-2773.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"1603_CR64","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1038\/s41591-020-0915-3","volume":"26","author":"A Zviran","year":"2020","unstructured":"Zviran A, Schulman RC, Shah M, Hill STK, Deochand S, Khamnei CC, et al. Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring. Nat Med. 2020;26:1114. https:\/\/doi.org\/10.1038\/s41591-020-0915-3.","journal-title":"Nat Med"},{"key":"1603_CR65","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1016\/j.ccell.2022.10.022","volume":"40","author":"A Jamshidi","year":"2022","unstructured":"Jamshidi A, Liu MC, Klein EA, Venn O, Hubbell E, Beausang JF, et al. Evaluation of cell-free DNA approaches for multi-cancer early detection. Cancer Cell. 2022;40:1537-1549.e12. https:\/\/doi.org\/10.1016\/j.ccell.2022.10.022.","journal-title":"Cancer Cell"},{"key":"1603_CR66","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.annonc.2020.02.011","volume":"31","author":"MCC Liu","year":"2020","unstructured":"Liu MCC, Oxnard GRR, Klein EAA, Swanton C, Seiden MVV, Cummings SR, et al. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Ann Oncol. 2020;31:745. https:\/\/doi.org\/10.1016\/j.annonc.2020.02.011.","journal-title":"Ann Oncol"},{"key":"1603_CR67","doi-asserted-by":"publisher","unstructured":"Paoli M. The MIMESIS dataset. https:\/\/doi.org\/10.5281\/zenodo.17781295.","DOI":"10.5281\/zenodo.17781295"},{"key":"1603_CR68","unstructured":"Paoli M. The METER computational framework. https:\/\/github.com\/caos-lab-unifi\/METER."}],"container-title":["Genome Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13073-026-01603-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13073-026-01603-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13073-026-01603-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T10:37:09Z","timestamp":1772620629000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13073-026-01603-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":68,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1603"],"URL":"https:\/\/doi.org\/10.1186\/s13073-026-01603-3","relation":{},"ISSN":["1756-994X"],"issn-type":[{"value":"1756-994X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,3]]},"assertion":[{"value":"1 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The trials included in this study received approval from the local institutional ethics committee of the Hospital of Prato and by the Area Vasta Toscana Centro and local Ethics Committee (CEAVC 15108; CEAVC 11252), in accordance with Helsinki Declaration. Written informed consent was prospectively obtained from all patients participating in these trials.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Authors declare that they have no competing interests related to this work. Out of this work, ER reports honoraria from Eisai; travel grants from Pfizer, Gilead Sciences; LM reports Honoraria from Pfizer, Novartis, Seagen; consulting or advisory role from Pfizer, Novartis, Seagen, Roche, Menarini Group; research funding from Pfizer, Novartis; travel, accommodations, expenses from Roche, Janssen, Gilead Sciences, Menarini Group; LB reports personal financial interests (Honoraria, consultancy or advisory role) from Amgen, AstraZeneca, Boehringer-Ingelheim, Daiichi-Sankyo, Eisai, Exact Sciences, Gilead, Lilly, Menarini, Novartis, Pfizer, Pierre Fabre, Roche, Sanofi, SeaGen; institutional financial interests from Celgene, Genomic Health, Novartis; travel grant from AstraZeneca, Daiichi-Sankyo. The remaining authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"27"}}